ABION Inc. (KOSDAQ:203400)

South Korea · Delayed Price · Currency is KRW

676.00

-14.00 (-2.03%)

At close: Aug 14, 2026

Market Cap	60.91B -66.6%
Revenue (ttm)	939.70M -8.0%
Net Income	-28.35B
EPS	-344.40
Shares Out	90.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,169,199
Open	711.00
Previous Close	690.00
Day's Range	650.00 - 784.00
52-Week Range	570.00 - 4,510.00
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2007

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 203400

Full Company Profile

Financial Performance

In 2025, ABION's revenue was 880.14 million, an increase of 15.86% compared to the previous year's 759.68 million. Losses were -29.06 billion, -33.00% less than in 2024.

Financial Statements